Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSloan, Derek James
dc.contributor.authorLewis, Joseph M.
dc.date.accessioned2016-04-20T15:16:51Z
dc.date.available2016-04-20T15:16:51Z
dc.date.issued2016-03
dc.identifier.citationSloan , D J & Lewis , J M 2016 , ' Management of multidrug-resistant TB : novel treatments and their expansion to low resource settings ' , Transactions of the Royal Society of Tropical Medicine and Hygiene , vol. 110 , no. 3 , trv107 , pp. 163-172 . https://doi.org/10.1093/trstmh/trv107en
dc.identifier.issn0035-9203
dc.identifier.otherPURE: 241920865
dc.identifier.otherPURE UUID: d5100b32-6ec4-43ca-ac36-97e958545097
dc.identifier.otherScopus: 84959899278
dc.identifier.urihttp://hdl.handle.net/10023/8652
dc.descriptionThis article received no specific funding. JL is supported by the Wellcome Trust as a clinical PhD fellow [grant number 109105/Z/15/Z].en
dc.description.abstractDespite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to undermine efforts to end theworldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in 'low' or 'low-middle' income countries. Shorter, all oral and less toxic multidrug combinations are required to improve treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofTransactions of the Royal Society of Tropical Medicine and Hygieneen
dc.rights© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.subjectBedaquilineen
dc.subjectDelamaniden
dc.subjectExtensively drug-resistanten
dc.subjectLinezoliden
dc.subjectMultidrug-resistanten
dc.subjectTuberculosisen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectQR180 Immunologyen
dc.subjectParasitologyen
dc.subjectInfectious Diseasesen
dc.subjectPublic Health, Environmental and Occupational Healthen
dc.subject.lccRA0421en
dc.subject.lccQR180en
dc.titleManagement of multidrug-resistant TB : novel treatments and their expansion to low resource settingsen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.identifier.doihttps://doi.org/10.1093/trstmh/trv107
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record